Myers' cocktail is an intravenous (IV) nutrient formulation that typically consists of a mixture of vitamins and minerals dissolved in a sterile saline or dextrose solution. The most common composition includes:
- Vitamin C (ascorbic acid) – 10 g to 30 g
- B‑complex vitamins – usually a combination of thiamine (B₁), riboflavin (B₂), niacinamide (B₃), pyridoxine (B₆), cyanocobalamin (B₁₂), and sometimes folic acid (B₉)
- Magnesium sulfate – 1 g to 2 g
- Calcium chloride – optional, 1 g to 2 g
- Sodium chloride (0.9 % saline) or 5 % dextrose as the carrier fluid
Origin and Naming
The formulation is named after John A. Myers, MD, a Baltimore‑based physician who, in the 1970s, began administering a similar combination of nutrients intravenously to patients with various chronic illnesses. Myers reported anecdotal improvements in fatigue, migraine, and fibromyalgia symptoms, and the preparation became associated with his name in clinical practice and later in alternative‑medicine circles.
Reported Uses
Practitioners who offer Myers' cocktail commonly market it for:
- Chronic fatigue syndrome
- Fibromyalgia
- Migraines and tension‑type headaches
- Seasonal affective disorder
- General immune support
- Post‑operative recovery
Evidence Base
The scientific literature contains limited, low‑quality evidence regarding the efficacy of Myers' cocktail:
| Condition | Study Design | Findings | Limitations |
|---|---|---|---|
| Chronic fatigue syndrome | Small open‑label trials (e.g., 20–30 participants) | Some participants reported reduced fatigue scores after multiple infusions | Lack of control groups, short follow‑up, potential placebo effect |
| Fibromyalgia | Case series and uncontrolled studies | Reports of short‑term pain reduction in a subset of patients | No randomized controlled trials (RCTs); outcomes not standardized |
| Migraine prophylaxis | Anecdotal reports; one small pilot study | Variable reduction in migraine frequency noted | Small sample size, no blinding |
Systematic reviews and meta‑analyses have concluded that, as of the latest available data (2023), there is insufficient high‑quality evidence to confirm the therapeutic benefits of Myers' cocktail for any specific medical condition. The observed improvements in some patients are often attributed to the placebo response, the correction of subclinical nutrient deficiencies, or the supportive care setting.
Safety Profile
The ingredients are generally recognized as safe when administered intravenously at appropriate doses. Reported adverse events are uncommon but can include:
- Phlebitis or infiltration at the IV site
- Allergic reactions (rare) to vitamins or mineral components
- Electrolyte disturbances (e.g., hypermagnesemia) if administered excessively or in patients with renal impairment
Patients with renal insufficiency, hypercalcemia, severe liver disease, or known hypersensitivity to any component should avoid the infusion, and clinicians typically assess renal function and electrolyte status before treatment.
Regulatory Status
In the United States, Myers' cocktail is not an FDA‑approved medication. It is classified as an IV nutrient supplement and is administered under the auspices of outpatient infusion centers, integrative‑medicine clinics, or by licensed health‑care providers who consider it a form of complementary therapy. Because it is not a drug, it is not subject to the same rigorous clinical‑trial requirements as pharmaceutical agents.
Professional Guidelines
Major medical organizations (e.g., the American College of Physicians, the American Academy of Neurology) have not issued formal guidelines endorsing the use of Myers' cocktail. The National Center for Complementary and Integrative Health (NCCIH) lists it under “IV vitamin therapy” and notes the lack of robust evidence supporting its efficacy.
Summary
Myers' cocktail is an IV infusion of a standard set of vitamins and minerals, originally devised by Dr. John A. Myers in the 1970s. While it is widely offered in alternative‑medicine settings for a variety of chronic conditions, the current body of peer‑reviewed research does not provide convincing evidence of specific clinical benefits beyond placebo or correction of overt deficiencies. The preparation is generally safe when administered correctly, but it remains an unapproved, non‑regulated therapeutic modality.
